rabbit polyclonal antibody specific to human egfl7 protein Search Results


90
R&D Systems goat polyclonal anti egfl7
Goat Polyclonal Anti Egfl7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat polyclonal anti egfl7/product/R&D Systems
Average 90 stars, based on 1 article reviews
goat polyclonal anti egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Novus Biologicals anti egfl7 antibody
Anti Egfl7 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti egfl7 antibody/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
anti egfl7 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
Proteintech antibody against egfl7
URRCC enhances <t>EGFL7</t> level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control
Antibody Against Egfl7, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against egfl7/product/Proteintech
Average 93 stars, based on 1 article reviews
antibody against egfl7 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Boster Bio egfl7
URRCC enhances <t>EGFL7</t> level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control
Egfl7, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfl7/product/Boster Bio
Average 90 stars, based on 1 article reviews
egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti human egfl7 r 12 antibody
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Anti Human Egfl7 R 12 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human egfl7 r 12 antibody/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
anti human egfl7 r 12 antibody - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

94
Proteintech notch4 antibody
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Notch4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/notch4 antibody/product/Proteintech
Average 94 stars, based on 1 article reviews
notch4 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

90
Abnova mouse-anti-egfl7
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Mouse Anti Egfl7, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse-anti-egfl7/product/Abnova
Average 90 stars, based on 1 article reviews
mouse-anti-egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Agilent technologies flex buffer
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Flex Buffer, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flex buffer/product/Agilent technologies
Average 90 stars, based on 1 article reviews
flex buffer - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Creative Biolabs humanized murine monoclonal antibody that binds to the egfl7 protein and inhibits its function (parsatuzumab)
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Humanized Murine Monoclonal Antibody That Binds To The Egfl7 Protein And Inhibits Its Function (Parsatuzumab), supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/humanized murine monoclonal antibody that binds to the egfl7 protein and inhibits its function (parsatuzumab)/product/Creative Biolabs
Average 90 stars, based on 1 article reviews
humanized murine monoclonal antibody that binds to the egfl7 protein and inhibits its function (parsatuzumab) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Creative Biolabs parsatuzumab
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Parsatuzumab, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/parsatuzumab/product/Creative Biolabs
Average 90 stars, based on 1 article reviews
parsatuzumab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc notch2
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Notch2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/notch2/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
notch2 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc hes1 antibodies
<t>Egfl7</t> mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.
Hes1 Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hes1 antibodies/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
hes1 antibodies - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


URRCC enhances EGFL7 level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: URRCC enhances EGFL7 level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Transfection, Quantitative RT-PCR, Control, Expressing, Immunohistochemistry

URRCC is associated with EGFL7/P-AKT/FOXO3 signaling pathway. a and b : WB analysis of T-AKT, P-AKT, and FOXO3 in URRCC-overexpressing or URRCC-inhibited A498 and OSRC-2 cells compared with sh-control or mock group, β-actin was used as a loading control. c : CCK8 assays of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. d : Representative images and the numbers of invasive cells per high-power field reduced after the transfection with mock/oe-URRCC and si-NC/si-EGFL7 in A498 cells. e : WB analysis for EGFL7, T-AKT, P-AKT, and FOXO3 protein levels of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. β-actin was used as a loading control

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: URRCC is associated with EGFL7/P-AKT/FOXO3 signaling pathway. a and b : WB analysis of T-AKT, P-AKT, and FOXO3 in URRCC-overexpressing or URRCC-inhibited A498 and OSRC-2 cells compared with sh-control or mock group, β-actin was used as a loading control. c : CCK8 assays of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. d : Representative images and the numbers of invasive cells per high-power field reduced after the transfection with mock/oe-URRCC and si-NC/si-EGFL7 in A498 cells. e : WB analysis for EGFL7, T-AKT, P-AKT, and FOXO3 protein levels of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. β-actin was used as a loading control

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Control, Transfection

A Schematic Diagram of LncRNA-URRCC-Based Signaling Pathway in ccRCC cells proliferation and invasion. LncRNA-URRCC upregulates AKT signaling by directly targeting EGFL7 via mediating histone H3 acetylation of EGFL7 promoter, and then inducing cell growth and invasion. AKT signaling downstream FOXO3 in turn downregulates URRCC by directly binding to its promoter

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: A Schematic Diagram of LncRNA-URRCC-Based Signaling Pathway in ccRCC cells proliferation and invasion. LncRNA-URRCC upregulates AKT signaling by directly targeting EGFL7 via mediating histone H3 acetylation of EGFL7 promoter, and then inducing cell growth and invasion. AKT signaling downstream FOXO3 in turn downregulates URRCC by directly binding to its promoter

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Binding Assay

Egfl7 mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: Egfl7 mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Expressing, Transgenic Assay, Construct, Quantitative RT-PCR, Isolation

Overexpressing Egfl7 results in partial embryonic lethality and hemorrhaging. (A) The expected and observed number of embryos and pups obtained from Tie2-Egfl7 hemizygous intercrosses at E9.5, E10.5, E12.5, and P5. *P = .004. (B) Gross phenotype of wild-type (i-ii) and Tie2-Egfl7 transgenic embryos (iii-iv) at E10.5 and E12.5. Arrows indicate hemorrhaging in Tie2-Egfl7 mice at E12.5 (iv). Original magnification ×20 (E10.5), ×12 (E12.5). Images were captured on Discovery V20 Stereomicroscope (Carl Zeiss).

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: Overexpressing Egfl7 results in partial embryonic lethality and hemorrhaging. (A) The expected and observed number of embryos and pups obtained from Tie2-Egfl7 hemizygous intercrosses at E9.5, E10.5, E12.5, and P5. *P = .004. (B) Gross phenotype of wild-type (i-ii) and Tie2-Egfl7 transgenic embryos (iii-iv) at E10.5 and E12.5. Arrows indicate hemorrhaging in Tie2-Egfl7 mice at E12.5 (iv). Original magnification ×20 (E10.5), ×12 (E12.5). Images were captured on Discovery V20 Stereomicroscope (Carl Zeiss).

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Transgenic Assay

Embryonic Egfl7 overexpression causes defects in the developing heart and in head and yolk sac vasculature. (A) CD31 immunostaining of whole-mount wild-type (i) and transgenic (v) embryos at E10.5. White and red lines represent the atrium (A) and ventricle (V), respectively. Original magnification ×30. CD31 immunostaining of parasagittal sections of wild-type (ii-iv) and Tie2-Egfl7 transgenic embryos (vi-viii). High-magnification images of black-boxed areas in subpanels ii and vi (iii,vii). High-magnification images of boxed areas in subpanels iii and vii (iv,viii). Original magnification ×1.25 (ii,vi), ×4 (iii,vii), and ×20 (iv,viii). Black asterisks represent reduction in traberculation; and red asterisks, branchial arch. (B) CD31 immunostaining of whole-mount embryos at E10.5. Tie2-Egfl7 transgenic embryos (iii-iv) showed abnormal endothelial aggregates (arrowheads), a decrease in the number of major cranial vessels (red dots), and increased branching (white dots) compared with wild-type littermates (i-ii). Original magnification ×60. (C) CD31 immunostaining of cross sections from wild-type (i-iv) and Tie2-Egfl7 transgenic embryos (v-viii) at E10.5. High-magnification images of black-boxed areas in subpanels i and v (ii,vi). High-magnification images of the boxed areas in subpanels iii and vii (iv,viii). Arrows indicates carotid artery (CA); and arrowheads, hemorrhaging from CA. Original magnification ×4 (i,iii,v,vii) and ×10 (ii,iv,vi,viii). (D) CD31 immunostaining of E12.5 wild-type (i-ii) and transgenic (iii-iv) yolk sacs. Arrowheads indicate vitelline vessels; and arrow, knot-like structure in vein. Quantification of vitelline vessel diameter in wild-type (□, n = 2) and transgenic (■, n = 4) yolk sacs. (v) *P < .03. Original magnification ×25.5 (i,iii) and × 41 (ii,iv). Whole-mount images were captured on Discovery V20 Stereomicroscope (Carl Zeiss) and immunohistochemistry images on the Axioplan 2 Imaging Upright Microscope (Carl Zeiss).

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: Embryonic Egfl7 overexpression causes defects in the developing heart and in head and yolk sac vasculature. (A) CD31 immunostaining of whole-mount wild-type (i) and transgenic (v) embryos at E10.5. White and red lines represent the atrium (A) and ventricle (V), respectively. Original magnification ×30. CD31 immunostaining of parasagittal sections of wild-type (ii-iv) and Tie2-Egfl7 transgenic embryos (vi-viii). High-magnification images of black-boxed areas in subpanels ii and vi (iii,vii). High-magnification images of boxed areas in subpanels iii and vii (iv,viii). Original magnification ×1.25 (ii,vi), ×4 (iii,vii), and ×20 (iv,viii). Black asterisks represent reduction in traberculation; and red asterisks, branchial arch. (B) CD31 immunostaining of whole-mount embryos at E10.5. Tie2-Egfl7 transgenic embryos (iii-iv) showed abnormal endothelial aggregates (arrowheads), a decrease in the number of major cranial vessels (red dots), and increased branching (white dots) compared with wild-type littermates (i-ii). Original magnification ×60. (C) CD31 immunostaining of cross sections from wild-type (i-iv) and Tie2-Egfl7 transgenic embryos (v-viii) at E10.5. High-magnification images of black-boxed areas in subpanels i and v (ii,vi). High-magnification images of the boxed areas in subpanels iii and vii (iv,viii). Arrows indicates carotid artery (CA); and arrowheads, hemorrhaging from CA. Original magnification ×4 (i,iii,v,vii) and ×10 (ii,iv,vi,viii). (D) CD31 immunostaining of E12.5 wild-type (i-ii) and transgenic (iii-iv) yolk sacs. Arrowheads indicate vitelline vessels; and arrow, knot-like structure in vein. Quantification of vitelline vessel diameter in wild-type (□, n = 2) and transgenic (■, n = 4) yolk sacs. (v) *P < .03. Original magnification ×25.5 (i,iii) and × 41 (ii,iv). Whole-mount images were captured on Discovery V20 Stereomicroscope (Carl Zeiss) and immunohistochemistry images on the Axioplan 2 Imaging Upright Microscope (Carl Zeiss).

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Over Expression, Immunostaining, Transgenic Assay, Immunohistochemistry, Imaging, Microscopy

Tie2-Egfl7 transgenic mice exhibit defects in vascular cell stratification at branch points of the dorsal aorta. Immunofluorescence staining of the dorsal aorta at E12.5. CD31+ cells are shown in green (Alexa Flour 488), and SMA+ cells are shown in red (Cy3). Images were captured on the TCS AOBS SP2 microscope (Leica). (A-B) Wild-type and transgenic dorsal aorta, respectively. Original magnification 20×/0.7NA, water objective. (C-D) High-magnification image of boxed areas in panels A and B. Original magnification 63×/1.2NA, water objective. (E) Summary of phenotypes observed in Egfl7 transgenic embryos.

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: Tie2-Egfl7 transgenic mice exhibit defects in vascular cell stratification at branch points of the dorsal aorta. Immunofluorescence staining of the dorsal aorta at E12.5. CD31+ cells are shown in green (Alexa Flour 488), and SMA+ cells are shown in red (Cy3). Images were captured on the TCS AOBS SP2 microscope (Leica). (A-B) Wild-type and transgenic dorsal aorta, respectively. Original magnification 20×/0.7NA, water objective. (C-D) High-magnification image of boxed areas in panels A and B. Original magnification 63×/1.2NA, water objective. (E) Summary of phenotypes observed in Egfl7 transgenic embryos.

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Transgenic Assay, Immunofluorescence, Staining, Microscopy

Overexpressing Egfl7 in the postnatal retina results in arterial and venous defects and an increase in vascular coverage. (A) Quantitative RT-PCR analysis of Egfl7 and miR126 expression in P5 retinas isolated from wild-type (□, n = 4) and transgenic (■, n = 6) mice. Egfl7 expression is normalized to endothelial cell number using CD31 expression. *P < .03. (B) Wild-type (i-iii) and transgenic (iv-vi) retinal vasculature at P5, stained with fluorescein isothiocyanate–labeled BS-1 lectin. Red dots represent branching at the distal ends of the vessel; white dots, branching along the vessel length; arrowheads, tortuous veins; and arrows, venous knot-like structures. Original magnification 10×/0.4NA, water objective (i,iv), 20×/0.7NA, water objective (ii,v), and 63×/1.2NA, (iii,vi). (C) Vascular coverage in wild-type (i) and transgenic (ii) retinas at P5. Boxed regions correspond to areas where coverage was measured. (iii) Average vascular coverage at the peripheral and central plexus for wild-type (□, n = 8) and transgenic (■, n = 14) retinas. *P < .05. (iv) CD31 mRNA expression in wild-type (□, n = 4) and transgenic (■, n = 6) retinas. Filopodia in wild-type (v) and transgenic (vi) retinas. (vii) Average filopodia number per 100-μM vessel length for wild-type (□, n = 5) and transgenic (■, n = 9) retinas. *P < .05. Values for vascular coverage and filopodia number are represented as fold difference relative to wild-type. Original magnification 20× (i,ii) and 40×/1.3NA, water objective (v,vi). (D) Summary of phenotypes observed in Egfl7 transgenic retinal vasculature at P5. Images of the retinal vasculature were captured on the TCS AOBS SP2 microscope (Leica), and filopodia was imaged using the LSM 5Live DuoScan microscope (Carl Zeiss).

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: Overexpressing Egfl7 in the postnatal retina results in arterial and venous defects and an increase in vascular coverage. (A) Quantitative RT-PCR analysis of Egfl7 and miR126 expression in P5 retinas isolated from wild-type (□, n = 4) and transgenic (■, n = 6) mice. Egfl7 expression is normalized to endothelial cell number using CD31 expression. *P < .03. (B) Wild-type (i-iii) and transgenic (iv-vi) retinal vasculature at P5, stained with fluorescein isothiocyanate–labeled BS-1 lectin. Red dots represent branching at the distal ends of the vessel; white dots, branching along the vessel length; arrowheads, tortuous veins; and arrows, venous knot-like structures. Original magnification 10×/0.4NA, water objective (i,iv), 20×/0.7NA, water objective (ii,v), and 63×/1.2NA, (iii,vi). (C) Vascular coverage in wild-type (i) and transgenic (ii) retinas at P5. Boxed regions correspond to areas where coverage was measured. (iii) Average vascular coverage at the peripheral and central plexus for wild-type (□, n = 8) and transgenic (■, n = 14) retinas. *P < .05. (iv) CD31 mRNA expression in wild-type (□, n = 4) and transgenic (■, n = 6) retinas. Filopodia in wild-type (v) and transgenic (vi) retinas. (vii) Average filopodia number per 100-μM vessel length for wild-type (□, n = 5) and transgenic (■, n = 9) retinas. *P < .05. Values for vascular coverage and filopodia number are represented as fold difference relative to wild-type. Original magnification 20× (i,ii) and 40×/1.3NA, water objective (v,vi). (D) Summary of phenotypes observed in Egfl7 transgenic retinal vasculature at P5. Images of the retinal vasculature were captured on the TCS AOBS SP2 microscope (Leica), and filopodia was imaged using the LSM 5Live DuoScan microscope (Carl Zeiss).

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Quantitative RT-PCR, Expressing, Isolation, Transgenic Assay, Staining, Labeling, Microscopy

EGFL7 functions as an antagonist of Notch in HUVECs. (A) Human EGFL7 expression in lentivirally generated HUVEC lines, as measured by quantitative RT-PCR. Empty lentiviruses pCCL GFP and pLKO served as controls for EGFL7 overexpression and knockdown, respectively. Data are represented as fold induction relative to the lentiviral controls. (B) Proliferation assay of HUVEC lines grown in complete medium for 4 days. (C) Capillary sprouting assay. Control (GFP and pLKO), EGFL7 overexpressing (EGFL7), and knockdown (pLKO 61) HUVEC lines were coated on a cytodex bead, beads embedded in fibrin gels, and visualized on day 7. (D) HUVEC monolayer wounding assay at 0 and 24 hours. Dotted lines highlight the edges of the monolayer. (E) Quantitation of HUVEC migration in monolayer wounding assay, represented as percentage of area filled at 8 hours. (F) Transactivation of Notch/CSL-luciferase reporter in EGFL7 overexpressing and knockdown HUVEC lines. Data represented as relative luciferase units (RLU). (G) Notch4-dependent HUVEC morphogenesis assay. Control HUVECs (pCCL-GFP or pLKO) or EGFL7 overexpressing (EGFL7) or knockdown (pLKO61) cells were grown as monolayer on a fibrin gel. GFP- or Notch4/GFP-expressing HUVECs were overlaid on top of the monolayer. At day 7, cocultures were visualized and the number of GFP+ cells undergoing morphogenesis, as seen by the extending of processes into the surrounding matrix per field, was determined. Experiments were performed in triplicate, and error bars represent SD.

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: EGFL7 functions as an antagonist of Notch in HUVECs. (A) Human EGFL7 expression in lentivirally generated HUVEC lines, as measured by quantitative RT-PCR. Empty lentiviruses pCCL GFP and pLKO served as controls for EGFL7 overexpression and knockdown, respectively. Data are represented as fold induction relative to the lentiviral controls. (B) Proliferation assay of HUVEC lines grown in complete medium for 4 days. (C) Capillary sprouting assay. Control (GFP and pLKO), EGFL7 overexpressing (EGFL7), and knockdown (pLKO 61) HUVEC lines were coated on a cytodex bead, beads embedded in fibrin gels, and visualized on day 7. (D) HUVEC monolayer wounding assay at 0 and 24 hours. Dotted lines highlight the edges of the monolayer. (E) Quantitation of HUVEC migration in monolayer wounding assay, represented as percentage of area filled at 8 hours. (F) Transactivation of Notch/CSL-luciferase reporter in EGFL7 overexpressing and knockdown HUVEC lines. Data represented as relative luciferase units (RLU). (G) Notch4-dependent HUVEC morphogenesis assay. Control HUVECs (pCCL-GFP or pLKO) or EGFL7 overexpressing (EGFL7) or knockdown (pLKO61) cells were grown as monolayer on a fibrin gel. GFP- or Notch4/GFP-expressing HUVECs were overlaid on top of the monolayer. At day 7, cocultures were visualized and the number of GFP+ cells undergoing morphogenesis, as seen by the extending of processes into the surrounding matrix per field, was determined. Experiments were performed in triplicate, and error bars represent SD.

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Expressing, Generated, Quantitative RT-PCR, Over Expression, Knockdown, Proliferation Assay, Control, Quantitation Assay, Migration, Luciferase

EGFL7 interacts with Notch receptors and regulates Notch target gene expression in vivo. (A) Alignment of the DSL domain of Jagged1, Serrate, Delta, and Lag-2 with the putative DSL domain in EGFL7. Red letters represent the consensus sequence. (B) Yeast-2-hybrid assay (left panel): EGFL7 interacts with NOTCH4 and DLL4. Full-length EGFL7, DLL4, or the extracellular domain of NOTCH4 were fused to either the DNA-binding domain or the transcriptional activation domain of GAL4, and protein-protein interactions were monitored by the ability of the transformed yeast to grow on defined medium, and expression of α-galactosidase. Yeast-3-hybrid assay (right panels): EGFL7 abolishes NOTCH4-DLL4 interaction. The Egfl7 ORF was cloned downstream of a methionine repressible promoter (Met25) and transformed into a yeast strain expressing Notch4-GAL activating domain and DLL4-GAL4 DNA-binding domain fusions. Expression of α-galactosidase was then assayed on X-gal selection plates with or without methionine. (Ci-ii) Coimmunoprecipitation assays with protein extracts prepared from HEK293 cells transfected with plasmids encoding MYC/His-tagged-Egfl7 and Notch4 ECD or Notch1 ECD. (i) A NOTCH4 antibody was used to immunoprecipitate NOTCH4 ECD, and protein complexes were probed for NOTCH4 and EGFL7 by Western blot. (ii) A MYC antibody was used to immunoprecipitate EGFL7, and protein complexes were probed for NOTCH1 and EGFL7 by Western blot. (iii) Coimmunoprecipitation assay with protein extracts prepared from HUVECs infected with an adenovirus encoding MYC-tagged-Egfl7. A MYC antibody was used to immunoprecipitate EGFL7, and protein complexes were probed for NOTCH1 and EGFL7 by Western blot. (iv) Coimmunoprecipitation assays using protein lysates prepared from E12.5 embryos. An antibody against NOTCH4 was used to immunoprecipitate NOTCH4, and protein complexes were probed for NOTCH4 and EGFL7 by Western blot. Vertical lines have been inserted to indicate a repositioned gel lane. (D) Notch target gene expression in wild-type (□, n = 4) and Tie2-Egfl7 transgenic (■, n = 6) retinas. Gene expression was measured by quantitative RT-PCR and normalized to endothelial cell number using CD31 expression. (E) Notch target gene expression in wild-type (white bars, n = 6) and Tie2-Egfl7 transgenic embryos (black bars, n = 4). Data are represented as fold change compared with wild-type. *P < .05.

Journal: Blood

Article Title: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

doi: 10.1182/blood-2010-03-274860

Figure Lengend Snippet: EGFL7 interacts with Notch receptors and regulates Notch target gene expression in vivo. (A) Alignment of the DSL domain of Jagged1, Serrate, Delta, and Lag-2 with the putative DSL domain in EGFL7. Red letters represent the consensus sequence. (B) Yeast-2-hybrid assay (left panel): EGFL7 interacts with NOTCH4 and DLL4. Full-length EGFL7, DLL4, or the extracellular domain of NOTCH4 were fused to either the DNA-binding domain or the transcriptional activation domain of GAL4, and protein-protein interactions were monitored by the ability of the transformed yeast to grow on defined medium, and expression of α-galactosidase. Yeast-3-hybrid assay (right panels): EGFL7 abolishes NOTCH4-DLL4 interaction. The Egfl7 ORF was cloned downstream of a methionine repressible promoter (Met25) and transformed into a yeast strain expressing Notch4-GAL activating domain and DLL4-GAL4 DNA-binding domain fusions. Expression of α-galactosidase was then assayed on X-gal selection plates with or without methionine. (Ci-ii) Coimmunoprecipitation assays with protein extracts prepared from HEK293 cells transfected with plasmids encoding MYC/His-tagged-Egfl7 and Notch4 ECD or Notch1 ECD. (i) A NOTCH4 antibody was used to immunoprecipitate NOTCH4 ECD, and protein complexes were probed for NOTCH4 and EGFL7 by Western blot. (ii) A MYC antibody was used to immunoprecipitate EGFL7, and protein complexes were probed for NOTCH1 and EGFL7 by Western blot. (iii) Coimmunoprecipitation assay with protein extracts prepared from HUVECs infected with an adenovirus encoding MYC-tagged-Egfl7. A MYC antibody was used to immunoprecipitate EGFL7, and protein complexes were probed for NOTCH1 and EGFL7 by Western blot. (iv) Coimmunoprecipitation assays using protein lysates prepared from E12.5 embryos. An antibody against NOTCH4 was used to immunoprecipitate NOTCH4, and protein complexes were probed for NOTCH4 and EGFL7 by Western blot. Vertical lines have been inserted to indicate a repositioned gel lane. (D) Notch target gene expression in wild-type (□, n = 4) and Tie2-Egfl7 transgenic (■, n = 6) retinas. Gene expression was measured by quantitative RT-PCR and normalized to endothelial cell number using CD31 expression. (E) Notch target gene expression in wild-type (white bars, n = 6) and Tie2-Egfl7 transgenic embryos (black bars, n = 4). Data are represented as fold change compared with wild-type. *P < .05.

Article Snippet: Samples were boiled at 100°C for 5 minutes, resolved, blotted on polyvinylidene difluoride membranes, and probed using either goat anti–human EGFL7 (R-12) antibody (Santa Cruz Biotechnology Sc34416, 1:1000), hamster anti–mouse Notch1 (Millipore MAB5414, 1:1000), goat anti–mouse Notch4 (E11; Santa Cruz Biotechnology Sc32634, 1:1000), or mouse anti–β-tubulin (Sigma-Aldrich T4026, 1:1000).

Techniques: Targeted Gene Expression, In Vivo, Sequencing, Y2H Assay, Binding Assay, Activation Assay, Protein-Protein interactions, Transformation Assay, Expressing, Hybrid Assay, Clone Assay, Selection, Transfection, Western Blot, Co-Immunoprecipitation Assay, Infection, Transgenic Assay, Gene Expression, Quantitative RT-PCR